Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children

NCT02852590 | Completed

• 1 other identifier: D21530
• Study Type: observational
• Target: 6,227
• Locations: 1 country
• Sites: 1

Brief Summary

Medications are the most commonly used clinical intervention and complications associated with their use are one of the most common causes of adverse events in health care. Adverse Drug Reactions (ADR) are a major cause of morbidity and pose a substantial burden on limited health care resources. Many drugs used to treat children in hospitals are either not licensed for use in children or are prescribed outside the terms of their product license (off-label prescribing). This is mainly due to the lack of clinical trials in this vulnerable population, and both practical difficulties and ethical considerations arising from involving children in clinical research. Drugs used within the specifications of the product license might be less likely to cause ADR compared to drugs that are either unlicensed or off-label for use in children. Few studies have shown a significant association between pediatric off-label drug use and ADR. To compare the probability of ADR after a licensed drug prescription versus the probability of ADR after prescribing a drug off-label in children, we are conducting a multi-center prospective observational study in different pediatric hospital wards in France. The availability of electronic health records made this study feasible. An automatic data extraction from hospital information systems has been implemented. A computer algorithm for determining pediatric drug labelling (i.e. off-label or unlicensed use) using the French summaries of product characteristics available in Thériaque® database has been developed. Detection of ADRs is carried out by health care professionals and research groups using a trigger tool and patients' electronic health records. The causality between ADRs and suspected medications is evaluated using the Naranjo and the French methods by regional pharmacovigilance centers. An independent pharmacovigilance board validates ADR evaluations, assesses both of their severity and avoidability, and indicates therapeutic alternatives to suspected medications. This is, to our knowledge, the first large multi-center and prospective study in France that evaluates the relationship between adverse drug reactions and unlicensed/ off-label drugs use in hospitalized children. The results of this study will provide more information on the prescription practice and the amplitude, nature and consequences of unlicensed/off-label drug use in hospitalized children. It will also help identify the risk factors of ADR that could be used to implement preventive actions, and guide future research in the field. An indirect benefit is represented by the increase of physicians' awareness in detecting and declaring ADRs and by communicating the results to the health professionals and to the public. This study is funded by ANSM (the French Medicine Agency).

Conditions

Hospitalized Children

Keywords

Observational; Pediatric; Off-Label Use; Unlicensed drug use; Adverse Drug Reaction; Hospitalized Children; Pediatric inpatients

Outcome Measures

Primary Outcomes (1)

• occurrence of an adverse drug reaction (ADR)

  To compare the probability of occurrence of an adverse drug reaction (ADR) after a licensed prescription drug versus the probability of occurrence of an ADR after prescribing a drug off-label or unlicensed in patients aged 0-15 years hospitalized at least 3 days.

  up to one month

Secondary Outcomes (6)

• proportion of pediatrics inpatients presenting at least one ADR

  up to one month

• indications for which drugs are prescribed in term of licensed/ unlicensed/ off-label manner by age group

  up to one month

• Identify the factors influencing the risk of developing ADRs after prescribing a drug

  up to one month

• causality of ADRs

  up to one month

• severity of ADRs

  up to one month

Eligibility Criteria

• Age: Up to 15 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

All eligible children will be recruited consecutively according to their hospital admission in the following wards : nephrology; hepato-gastroenterology; intensive care unit; endocrinology; child psychiatry; neurology; pneumology; pediatric cardiology; epilepsy, sleep and pediatric neurophysiology; general pediatrics.

You may qualify if:

• Children from 0 to 15 years old \[0 ; 15\[ (including term and preterm newborn infants).
• Hospitalised for at least 3 days.
• Receiving at least one medication.

You may not qualify if:

• Children aged 15 to 18 years old \[15 ; 18\]
• Children hospitalized for an Adverse Drug Reaction or undergoing voluntary drug detoxification.
• Children who did not take any drugs during their hospital stay.

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Pediatric Clinical Research and Investigation Centre CIC 1407 Inserm-UMR 5558 CNRS Lyon University & Hospices Civils de Lyon

Lyon, 69003, France

Location

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Study Officials

• Behrouz KASSAI, Pr

  Pediatric Clinical Research and Investigation Centre CIC 1407 Inserm-UMR 5558 CNRS Lyon University & Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2016
• First Posted: August 2, 2016
• Study Start: November 1, 2013
• Primary Completion: January 1, 2016
• Study Completion: January 1, 2016
• Last Updated: August 2, 2016

Record last verified: 2016-07

Locations

FR (1)